[Home thrombolysis for myocardial infarction. A multicenter study of the feasibility and evaluation of short-term prognosis]

Presse Med. 1988 Jun 4;17(22):1143-6.
[Article in French]

Abstract

It has been proven since 1986 that in myocardial infarction the sooner thrombolysis is performed the better. Forty-four patients were selected to enter a double-blind randomized trial in which they received either an acylated plasminogen streptokinase activator complex or a placebo. The injections were given intravenously at home within the first 3 hours (within the first 2 hours in 26 of them), by doctors from Mobile care units. This home treatment in the acute phase made it possible to gain 75 minutes on average, and up to 90 minutes when it was performed by an anaesthetist trained in emergency management. No serious complication, such as haemorrhagic or allergic reaction, occurred, and arrhythmia was no more frequent in the treated group than in the placebo group. Home thrombolysis did not delay admission to a cardiology Intensive Care unit (66 min. versus 64 min). Mean coronary patency was 75 per cent, and up to 82 per cent, in patients treated within 2 hours of the first symptoms. There was no significant difference between areas of reperfused or not reperfused patients in relation to time (P less than 0.08). Diagnosis sensitivity was 100 per cent. Thus, home thrombolysis is feasible and safe when performed by trained emergency medical teams and when criteria for inclusion and exclusion are fulfilled.

Publication types

  • Clinical Trial
  • English Abstract
  • Randomized Controlled Trial

MeSH terms

  • Double-Blind Method
  • Emergencies
  • Female
  • Fibrinolytic Agents / therapeutic use*
  • Home Care Services*
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction / drug therapy*
  • Prognosis
  • Random Allocation
  • Time Factors

Substances

  • Fibrinolytic Agents